Cefixime is an antibiotic applied across therapeutic domains involving acute or disruptive symptom patterns caused by susceptible bacteria. It is used in situations involving certain distressing symptoms across several key areas: acute otitis media, pharyngitis, tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated urinary tract infections (UTIs), uncomplicated gonorrhea, typhoid fever, and shigellosis.

The medication helps address symptoms that interfere with daily functioning during acute episodes. It is commonly used when short-term symptomatic assistance is needed for symptom clusters that may become intense or disruptive. This provides supportive relief when symptoms linked to inflammatory or irritative states, such as fever, painful urination, or earache, create noticeable functional strain.

“It is commonly used across conditions presenting with acute episodes that require targeted support for symptom management.”

---

Quick Fact: Managing Acute Discomfort

Property	Description
Primary Symptom Focus	Fever, localized pain (throat/ear), dysuria (painful urination)
Core Benefit	Supports easing the overall symptom load during acute episodes
Target Conditions	Conditions involving acute or disruptive bacterial manifestations
Clinical Scenario	Used during phases when symptoms become more noticeable

Eligibility Map: Who Can and Cannot Use Супракс (Cefixime)

Cefixime is officially contraindicated in patients with a known history of hypersensitivity to Cefixime, any other cephalosporin antibacterial agent, or a history of severe allergy to penicillins.

Age and Physiological Status

Category	Official Regulatory Statement
Pediatric Use	Safety and effectiveness are not established for infants under 6 months of age.
Renal Function	Dose adjustment is required in adults whose creatinine clearance (CrCl) is less than 60 mL/min.
Pregnancy	Classified as Category B; use is allowed only if clearly needed.
Lactation	Not recommended; consideration should be given to temporarily discontinuing nursing.
Gastrointestinal	Use with caution in patients with a history of colitis or other gastrointestinal disease.

Eligibility Summary

Regulatory documents establish that only adults and children 6 months and older with no history of severe beta-lactam allergy are officially eligible for Cefixime use under standard conditions. Population non-eligibility is explicitly mandated for patients with documented hypersensitivity reactions, while use is conditionally restricted or requires specific management for groups with severely impaired renal function or a history of colitis.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cefixime based on pharmacokinetic changes and pharmacodynamic effects with specific classes of co-administered substances. No medicinal products are formally classified as contraindicated solely due to interaction risk.

---

Documented Pharmacokinetic and Clearance Interactions

Interacting Substance	Official Regulatory Outcome
Probenecid	Increases Cefixime's peak serum concentration (Cmax) and overall exposure (AUC) by reducing its renal clearance.
Salicylates ( 650 mg oral dose)	Documented to decrease Cefixime's peak serum concentration (Cmax) and overall exposure (AUC) by 20-25%.
Carbamazepine	Elevated plasma levels of Carbamazepine have been reported during co-administration with Cefixime.

---

Pharmacodynamic and Coagulation Effects

Co-administration with coumarin-type anticoagulants, such as Warfarin, is officially associated with reported increases in prothrombin time (PT), indicating an enhanced anticoagulant effect. Regulatory information notes that patients with renal or hepatic impairment or a poor nutritional state are considered to be at increased risk for this effect, particularly when receiving prolonged therapy.

Laboratory Test Constraints

Cefixime may cause documented false positive reactions for glucose in the urine when tests based on Benedict’s solution or Fehling’s solution are used. A potential for a false positive direct Coombs test should also be recognized, consistent with other cephalosporin agents. Food consumption increases the time required to reach maximal absorption, but the overall absorption percentage remains similar.

The action of Cefixime, the active substance in Супракс, is a rapid and targeted bactericidal mechanism, primarily focused on the structural integrity of susceptible bacteria.

Targeting Penicillin-Binding Proteins (PBPs)

Cefixime acts as an irreversible inhibitor of D,D-transpeptidases, which are essential enzymes located in the bacterial cell wall and collectively known as Penicillin-Binding Proteins (PBPs). The drug's mechanism is defined by its ability to chemically bind to and inactivate these specific targets.

Initiating Cell Wall Lysis

Inactivating the PBPs halts the final, cross-linking step of the peptidoglycan synthesis pathway, which is vital for cell wall strength. The structural failure rapidly triggers the lysis (rupture) of the bacterial cell due to high internal osmotic pressure, resulting in the direct bactericidal consequence of cell death.

Constraints and Enzymatic Resistance

While Cefixime is chemically stable against many bacterial beta-lactamase enzymes, the mechanism is limited by resistance mechanisms, such as the production of Extended Spectrum beta-Lactamases (ESBLs), or when bacteria structurally alter the PBP targets, which reduces the drug's binding affinity and prevents the fatal cascade.

Cefixime is administered exclusively by the oral route and is available in forms including capsules, film-coated tablets, chewable tablets, and a powder for oral suspension. The standard adult regimen involves a total daily dose of 400 mg, which may be taken once daily or divided into 200 mg doses administered every 12 hours. Capsules and tablets can be ingested without regard to the timing of meals. The powder for suspension requires reconstitution with water and must be shaken prior to use, and chewable forms must be crushed or chewed before swallowing to ensure proper administration.

The duration of the therapeutic course is typically determined by the clinical scenario, generally ranging from seven to fourteen days. For certain infections caused by Streptococcus pyogenes, a minimum treatment period of ten days is required to ensure the elimination of the pathogen. A notable exception to the multi-day regimen is the treatment of uncomplicated gonorrhea, which is prescribed as a single 400 mg oral dose.

Specific adjustments to the dosing schedule are required for certain populations. Pediatric patients (6 months to 12 years) generally receive a dose calculated at 8 mg per kilogram of body weight per day. Furthermore, dose reduction to 200 mg once daily is necessary for adults with documented severe renal impairment (creatinine clearance ≤ 20 mL/min) to align with physiological drug clearance. If a scheduled dose is missed, the next dose should be taken at the regular time, and the missed dose should not be doubled.

Research Evidence / Overview of Studies for Suprax (Cefixime)

This overview summarizes the type of research that has been conducted to understand Cefixime, focusing on the study structures and what findings have been observed in regulated clinical settings. It does not provide medical advice or instructions on use.

Evidence for Infections of the Ear, Throat, and Tonsils

Research exploring the use of Cefixime for conditions like Acute Otitis Media (AOM) has primarily been conducted through Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms and examined outcomes related to physical discomfort. Cefixime was studied for its ability to influence bacteriological eradication, and studies observed patterns related to bacteriological eradication measurements in the short term. For children with AOM, studies monitored clinical cure rates and explored findings against other established antibiotic options. Long-term effects following the completion of therapy are not fully established, as follow-up durations were limited.

Evidence for Urinary Tract and Sexually Transmitted Infections

The evidence base for Uncomplicated Urinary Tract Infections (UTIs) and Uncomplicated Gonorrhea includes RCTs and continuous surveillance. Cefixime was observed in trials exploring temporary physiological imbalance, where research examined outcomes reflecting daily functioning. Studies monitored two main outcome types: measurements of bacteriological eradication and patient-reported outcomes describing perceived discomfort. For uncomplicated gonorrhea, research focused on single-dose regimens, and studies monitored patterns related to pathogen eradication measurements.

However, evidence quality varies across studies due to rapidly changing resistance patterns, and findings were mixed globally. The measured response in the studies was highly dependent on the local prevalence of resistant strains. Comparative evidence is lacking for Cefixime against some newer agents in certain common infections, and data are still emerging regarding the patterns of Cefixime response against rapidly evolving antimicrobial resistance.

Evidence in Specific Patient Populations

Cefixime was studied for its use in pediatric populations (children) for several key indications, and the oral suspension formulation was evaluated in trials assessing short-term symptom patterns in this younger population. However, data for certain groups, such as the very frail older adult population or pregnant individuals, remain insufficient within the core efficacy trials. The available research describes group patterns, not personal outcomes, and results apply primarily to the populations specifically studied in the controlled settings.

Key Studies & References Cefixime (StatPearls - NCBI Bookshelf)

Common questions about Супракс (FAQ)

---

Q: Is Супракс a strong antibiotic?

Official information classifies Cefixime, the active ingredient in Супракс, as a third-generation cephalosporin. It is also designated as a broad-spectrum and bactericidal agent. Its action involves killing susceptible bacteria by interfering with their cell structure, as described in regulatory documents.

---

Q: Why is Супракс sometimes preferred over other antibiotics?

Regulatory documents indicate that Супракс is a third-generation cephalosporin, offering activity against a wide range of bacteria. Additionally, the drug is an oral medication available in different forms and, for some specific infections, can be administered in a once-daily regimen, which is a factor noted in official product information regarding its usability.

---

Q: What should I expect after the first few doses of Супракс?

The active substance in Супракс has a rapid bactericidal action on susceptible bacteria. Regulatory advice emphasizes that it is important to continue taking the medication for the full prescribed duration to support the elimination of the pathogen, even if symptoms appear to improve early on.

---

Q: Why is it important to finish the full course of Супракс?

Official patient information stresses the necessity of completing the full course of antibiotics, even after symptoms are gone. Stopping the medication too soon or skipping doses may increase the risk of developing a drug-resistant bacterial infection.

---

Q: Are there official restrictions on driving while using Супракс?

Regulatory documents advise that if certain rare side effects occur, such as dizziness or encephalopathy (a serious condition affecting the brain that may cause confusion), individuals are advised to avoid operating machines or driving a vehicle.

---

Q: What kind of research has been done on Супракс for respiratory infections?

The official indications for Cefixime, according to regulatory documents, include the treatment of certain infections of the upper respiratory tract. These can include conditions such as pharyngitis (sore throat) and tonsillitis when they are caused by susceptible strains of designated microorganisms.

---

Q: Is Супракс effective against common ear infections?

Cefixime is formally indicated for the treatment of Acute Otitis Media, which is a common type of middle ear infection. It is used when the infection is caused by specific, susceptible microorganisms, as defined in regulatory labels.

---

Q: Is Супракс effective for treating urinary tract infections (UTIs)?

Cefixime is formally indicated for treating uncomplicated urinary tract infections (UTIs). This use is restricted to infections caused by specific strains of bacteria that are susceptible to the drug, as described in regulatory labels.

---

Q: Does the efficacy of Супракс change with age?

The effectiveness of the medication is tied to appropriate dosing. Regulatory information indicates that the safety and effectiveness are not established for infants under 6 months of age. Dosage adjustments based on weight are necessary for children, and adjustments based on renal (kidney) function may be required for older adults.

---

Q: What is the purpose of the 'Warnings' section in the official labeling for Супракс?

Regulatory agencies use the Warnings and Precautions sections to communicate critical safety information. This includes details about the potential for serious adverse reactions, such as severe allergic reactions and intestinal issues like Clostridium difficile-associated diarrhea (CDAD). It also highlights necessary special management, like dose adjustments for renal impairment.

---

Q: Is it acceptable to open the Супракс capsule and mix the powder with food?

Regulatory documents note that the capsule form is intended to be swallowed whole and not cut, broken, or chewed. A separate oral suspension form is available for patients, particularly children, who may have difficulty swallowing solid medication.

---

Q: Is Супракс used for colds or the flu?

Cefixime is an antibiotic designed to treat bacterial infections. Official regulatory information explicitly states that it will not work against illnesses caused by viruses, such as the common cold or the flu.

---

Q: Does Супракс interact with common pain relievers?

Official regulatory documents specifically list an interaction with Salicylates (aspirin in a specific dose), which may decrease the overall exposure of Cefixime by 20-25%. The core regulatory label does not specifically address interactions with all other common non-steroidal pain relievers.

---

Q: Does Супракс interact with birth control pills?

Regulatory documents and patient information for some oral contraceptives note that certain antibiotics may reduce the effectiveness of these medications. This interaction could lead to an increased risk for pregnancy or breakthrough bleeding.

---

Q: Are there any foods or drinks to avoid while taking Супракс?

Official information states that this medication can be taken with or without food. While taking it with food may slightly increase the time it takes to reach maximum absorption, the overall amount of drug absorbed remains similar. No specific foods or drinks are formally mandated to be avoided.

---

Q: How long does Супракс stay in the body after the last dose?

Official pharmacokinetic data shows that in adults with normal kidney function, the medication has a serum elimination half-life of approximately 2.4 to 4 hours. This time frame indicates how quickly the drug is processed and cleared from the body.

---

Q: Does Супракс have a black box warning in official documents?

A review of the official U.S. regulatory product labeling (SPL) indicates that Cefixime does not have a 'Black Box Warning'. This is the FDA's most stringent warning reserved for drugs with certain serious risks.

---

Q: Is there any information on long-term effects of using Супракс?

The drug is officially prescribed for the treatment of acute infections. Regulatory documents warn that prolonged use of nearly any antibiotic carries a risk of developing an overgrowth of resistant organisms or serious intestinal conditions.

---

Q: Is Супракс prescribed for skin infections?

Official regulatory indications for Cefixime do not explicitly list 'skin infections.' However, authoritative monographs classify Cefixime as a broad-spectrum antibiotic used to treat susceptible bacteria.

---

Q: Is there a risk of developing a yeast infection after using Супракс?

Patient safety information notes that use of this medication for prolonged or repeated periods can disrupt the body's natural balance of microorganisms. This disruption may result in the development of a new vaginal or oral fungal (yeast) infection.

---

Q: Are there any known interactions between Супракс and vaccines?

Official drug interaction data indicates that Cefixime may reduce the therapeutic efficacy of the BCG vaccine. No other common vaccines are listed with specific interactions in the core regulatory documents.

---

Q: Why is a prescription necessary for Супракс?

Cefixime is classified as a prescription-only drug because it is an antibiotic. Regulatory documents state that prescribing it in the absence of a proven or strongly suspected bacterial infection increases the risk of promoting the development of drug-resistant bacteria.

---

Q: Is Супракс known to affect sleep?

While regulatory documents do not list insomnia as a common side effect, they do report rare adverse events that affect the central nervous system. These include confusion and seizures, which are factors that can potentially impact alertness and rest.

---

Q: What is the main function of the inactive ingredients in Супракс?

The inactive ingredients, or excipients, are listed in official product labeling. Their primary function is to provide the medication with its form, flavor, stability, and structure. They ensure the active ingredient is delivered and absorbed properly.

---

Q: Are there any specific liver problems associated with Супракс?

Regulatory documents mention that a decrease in prothrombin activity (a clotting factor) may occur in patients with pre-existing hepatic (liver) impairment. Furthermore, some official adverse reaction lists have included reports of temporary increases in liver enzymes.

---

Q: Does Супракс treat both Gram-positive and Gram-negative bacteria?

Regulatory documents describe Cefixime as having activity against a wide variety of both Gram-positive organisms and Gram-negative organisms. However, it is noted that most Staphylococci and Enterococci bacteria are resistant to it.

Official Storage and Disposal Guidelines for Suprax (Cefixime)

Dosage Form	Storage Condition	Stability/Handling
Tablets, Capsules, Dry Powder	Room temperature (e.g., 59 F to 86 F / 15 C to 30 C)	Keep container tightly closed; protect from excess heat and moisture.
Reconstituted Suspension	Room temperature or refrigerated	Must be discarded after 14 days from the time of mixing.

All forms of this medication must be stored in the original, tightly closed container and kept out of the sight and reach of children, with safety caps securely locked.

For disposal, utilize drug take-back programs or mail-back envelopes when possible. If these options are unavailable, mix the medicine with an undesirable substance (such as dirt or coffee grounds) and place the mixture into a sealed container before discarding it in the household trash. The medication is not included on the list of drugs recommended for flushing down the toilet.